Thalassemia: Current approach to an old disease

Pediatric Clinics of North America

Volumn 49, Issue 6, 2002, Pages 1165-1191

  Lo, Louise ^a   Singer, Sylvia Titi ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASCORBIC ACID; BISPHOSPHONIC ACID DERIVATIVE; BUTYRIC ACID; CALCIUM; DEFEROXAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ESTROGEN; GROWTH HORMONE; HEMOGLOBIN F; HYDROXYUREA; IRON; RIBAVIRIN; SEX HORMONE; TESTOSTERONE; VITAMIN D;

ALLOIMMUNIZATION; ALPHA THALASSEMIA; AUTOIMMUNITY; BETA THALASSEMIA; BLOOD TRANSFUSION; BODY BURDEN; BONE DISEASE; BONE MARROW TRANSPLANTATION; CHELATION THERAPY; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DYSPLASIA; ENDOCRINE DISEASE; EYE DISEASE; GENE THERAPY; HEARING LOSS; HEART DISEASE; HEMOGLOBIN SYNTHESIS; HEMOLYSIS; HETEROZYGOTE DETECTION; HUMAN; HYPERCOAGULABILITY; INFECTIOUS COMPLICATION; INFECTIOUS HEPATITIS; IRON OVERLOAD; KIDNEY DISEASE; LIVER DISEASE; LUNG TOXICITY; PATHOPHYSIOLOGY; PRENATAL DIAGNOSIS; REVIEW; SCREENING TEST; SPLENECTOMY; THALASSEMIA INTERMEDIA;

BLOOD TRANSFUSION; BONE MARROW TRANSPLANTATION; CHILD; GENE THERAPY; HEMOGLOBINS; HUMANS; MUTATION; PRENATAL DIAGNOSIS; THALASSEMIA; WORLD HEALTH;

EID: 0036976639     PISSN: 00313955     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0031-3955(02)00088-3     Document Type: Review

References (114)

1. Cooley T, Lee PA. A series of cases of splenomegaly in children with anemia and peculiar bone changes. Trans Am Pediatr Soc 1925;37:29-30.
2. Weatherall DJ. Common genetic disorders of the red cell and the 'malaria hypothesis.' Ann Trop Med Parasitol 1987;81(5):539-48.
3. Flint J, et al. The population genetics of the haemoglobinopathies. Baillieres Clin Haematol 1993;6(1):215-62.
4. Allen SJ, et al. Alpha+-thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci USA 1997;94(26):14736-41.
5. Pearson HA, et al. The changing profile of homozygous beta-thalassemia: demography, ethnicity, and age distribution of current North American patients and changes in two decades. Pediatrics 1996;97(3):352-6.
6. Angastiniotis M, Modell B. Global epidemiology of hemoglobin disorders. Ann NY Acad Sci 1998;850:251-69.
7. Wood WG, Weatherall DJ. Developmental genetics of the human haemoglobins. Biochem J 1983;215(1):1-10.
8. Lucarelli G, et al. Bone marrow transplantation in patients with thalassemia. N Engl J Med 1990;322(7):417-21.
9. Issaragrisil S, et al. Transplantation of cord-blood stem cells into a patient with severe thalassemia [brief report]. N Engl J Med 1995;332(6):367-9.
10. Weatherall DJ. Thalassemia in the next millennium [keynote address]. Ann NY Acad Sci 1998;850:1-9.
11. Rund D, Rachmilewitz E. Pathophysiology of alpha- and beta-thalassemia: therapeutic implications. Semin Hematol 2001;38(4):343-9.
12. Weatherall DJ. Pathophysiology of thalassaemia. Baillieres Clin Haematol 1998;11(1):127-46.
13. Kazazian Jr HH. The thalassemia syndromes: molecular basis and prenatal diagnosis in 1990. Semin Hematol 1990;27(3):209-28.
14. Winichagoon P, et al. Genetic factors affecting clinical severity in beta-thalassemia syndromes. J Pediatr Hematol Oncol 2000;22(6):573-80.
15. Weatherall DJ. The phenotypic diversity of monogenic disease: lessons from the thalassemias. Harvey Lect 1998;94:1-20.
16. Laosombat V, et al. Clinical and hematological features of codon 17, A-T mutation of betathalassemia in Thai patients. Eur J Haematol 2001;66(2):126-9.
17. Weatherall DJ. Single gene disorders or complex traits: lessons from the thalassaemias and other monogenic diseases. BMJ 2000;321(7269):1117-20.
18. Higgs DR, et al. The alpha-thalassemias. Ann NY Acad Sci 1990;612:15-22.
19. Wy CA, et al. Outcome of infants with a diagnosis of hydrops fetalis in the 1990s. Am J Perinatol 1999;16(10):561-7.
20. Cao A, Galanello R, Rosatelli MC. Prenatal diagnosis and screening of the haemoglobinopathies. Baillieres Clin Haematol 1998;11(1):215-38.
21. Rogers M, Phelan L, Bain B. Screening criteria for beta thalassaemia trait in pregnant women. J Clin Pathol 1995;48(11):1054-6.
22. Tang DC, et al. Rapid differentiation of five common alpha-thalassemia genotypes by polymerase chain reaction. J Lab Clin Med 2001;137(4):290-5.
23. Telfer P, De la Salle B, Ridler C. Antenatal testing for haemoglobinopathies. Br J Haematol 2000;110(4):1003-4.
24. Petrou M, et al. Antenatal diagnosis. How to deliver a comprehensive service in the United Kingdom. Ann NY Acad Sci 1990;612:251-63.
25. Alter BP. Antenatal diagnosis. Summary of results. Ann NY Acad Sci 1990;612:237-50.
26. Wilson RD. Amniocentesis and chorionic villus sampling. Curr Opin Obstet Gynecol 2000; 12(2):81-6.
27. Stranc LC, Evans JA, Hamerton JL. Chorionic villus sampling and amniocentesis for prenatal diagnosis. Lancet 1997;349(9053):711-4.
28. Old J. Haemoglobinopathies. Prenat Diagn 1996;16(13):1181-6.
29. Kazazian Jr HH, et al. Gene defects in beta-thalassemia and their prenatal diagnosis. Ann NY Acad Sci 1990;612:1-14.
30. Thein SL. Beta-thalassaemia. Baillieres Clin Haematol 1998;11(1):91-126.
31. Weatherall DJ. Phenotype-genotype relationships in monogenic disease: lessons from the thalassaemias. Natl Rev Genet 2001;2(4):245-55.
32. Lorey F. California newborn screening and the impact of Asian immigration on thalassemia. Int J Ped 1997;4:11-6.
33. Wongchanchailert M, Laosombat V, Maipang M. Hemoglobin H disease in children. J Med Assoc Thai 1992;75(11):611-8.
34. Chui DH, Waye JS. Hydrops fetails caused by alpha-thalassemia: an emerging health care problem. Blood 1998;91(7):2213-22.
35. Singer ST, et al. Changing outcome of homozygous alpha-thalassemia: cautious optimism. J Pediatr Hematol Oncol 2000;22(6):539-42.
36. Piomelli S, Loew T. Management of thalassemia major (Cooley's anemia). Hematol Oncol Clin N Am 1991;5(3):557-69.
37. Piomelli S. The management of patients with Cooley's anemia: transfusions and splenectomy. Semin Hematol 1995;32(4):262-8.
38. al-Salem AH, al-Dabbous I, Bhamidibati P. The role of partial splenectomy in children with thalassemia. Eur J Pediatr Surg 1998;8(6):334-8.
39. Wonke B. Clinical management of beta-thalassemia major. Semin Hematol 2001;38(4):350-9.
40. Prati D, et al. A multicenter prospective study on the risk of acquiring liver disease in antihepatitis C virus negative patients affected from homozygous beta-thalassemia. Blood 1998;92(9):3460-4.
41. Hershko C, Link G, Cabantchik I. Pathophysiology of iron overload. Ann NY Acad Sci 1998;850:191-201.
42. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89(3):739-61.
43. Brittenham GM, et al. Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major. N Engl J Med 1994;331(9):567-73.
44. Conrad ME, Umbreit JN, Moore EG. Iron absorption and transport. Am J Med Sci 1999;318(4):213-29.
45. Olivieri N. Advances in iron chelation therapy in thalassemia. Int J Ped Hematol Oncol 1997;4:53-66.
46. Grady RW, Giardina PJ. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998;339(23):1712-3 discussion 1713-4.
47. Breuer W, et al. Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy. Blood 2001;97(3):792-8.
48. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341(2):99-109.
49. Hershko C, Weatherall DJ. Iron-chelating therapy. Crit Rev Clin Lab Sci 1988;26(4):303-45.
50. de Virgiliis S, et al. Serum ferritin, liver iron stores, and liver histology in children with thalassaemia. Arch Dis Child 1980;55(1):43-5.
51. Zurlo MG, et al. Survival and causes of death in thalassaemia major. Lancet 1989;2(8653):27-30.
52. Aessopos A, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood 2001;97(11):3411-6.
53. Jessup M, Manno CS. Diagnosis and management of iron-induced heart disease in Cooley's anemia, Ann NY Acad Sci 1998;850:242-50.
54. Vecchio C, Derchi G. Management of cardiac complications in patients with thalassemia major. Semin Hematol 1995;32(4):288-96.
55. Wang ZJ, et al. Evaluation of iron overload by single voxel MRS measurement of liver T2. J Magn Reson Imaging 2002;15(4):395-400.
56. Olivieri NF, et al. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994;331(9):574-8.
57. Koerner MM, et al. Heart transplantation for end-stage heart failure caused by iron overload. Br J Haematol 1997;97(2):293-6.
58. Bonkovsky HL, Lambrecht RW. Iron-induced liver injury. Clin Liver Dis 2000;4(2):409-29 [vi-vii].
59. Iancu TC, Neustein HB. Ferritin in human liver cells of homozygous beta-thalassaemia: ultrastructural observations. Br J Haematol 1977;37(4):527-35.
60. Niederau C, et al. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110(4):1107-19.
61. Angelucci E. Antibodies to hepatitis C virus in thalassemia. Haematologica 1994;79(4):353-5.
62. Busch MP, Dodd RY. NAT and blood safety: what is the paradigm? Transfusion 2000;40(10):1157-60.
63. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001;345(1):41-52.
64. Tong MJ, et al. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med 1995;332(22):1463-6.
65. Telfer PT, et al. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in thalassaemic patients. Br J Haematol 1997;98(4):850-5.
66. Borgna-Pignatti C, et al. Growth and sexual maturation in thalassemia major. J Pediatr 1985;106(1):150-5.
67. Borgna-Pignatti C, et al. Survival and disease complications in thalassemia major. Ann NY Acad Sci 1998;850:227-31.
68. Jensen CE, et al. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol 1997;59(2):76-81.
69. Caruso-Nicoletti M, et al. Short stature and body proportion in thalassaemia. J Pediatr Endocrinol Metab 1998;11(Suppl 3):S811-6.
70. Roth C, et al. Short stature and failure of pubertal development in thalassaemia major: evidence for hypothalamic neurosecretory dysfunction of growth hormone secretion and defective pituitary gonadotropin secretion. Eur J Pediatr 1997;156(10):777-83.
71. De Virgiliis S, et al. Deferoxamine-induced growth retardation in patients with thalassemia major. J Pediatr 1988;113(4):661-9.
72. Kattamis CA, Kattamis AC. Management of thalassemias: growth and development, hormone substitution, vitamin supplementation, and vaccination. Semin Hematol 1995;32(4):269-79.
73. Cavallo L, et al. Short-term therapy with recombinant growth hormone in polytransfused thalassaemia major patients with growth deficiency. J Pediatr Endocrinol Metab 1998;11(Suppl 3):S845-9.
74. Grundy RG, et al. Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. Arch Dis Child 1994;71(2):128-32.
75. Gulati R, Bhatia V, Agarwal SS. Early onset of endocrine abnormalities in beta-thalassemia major in a developing country. J Pediatr Endocrinol Metab 2000;13(6):651-6.
76. Karagiorga-Lagana M. Fertility in thalassemia: the Greek experience. J Pediatr Endocrinol Metab 1998;11(Suppl 3):945-51.
77. Jensen CE, Tuck SM, Wonke B. Fertility in beta thalassaemia major: a report of 16 pregnancies, pre conceptual evaluation and a review of the literature. Br J Obstet Gynaecol 1995;102(8):625-9.
78. Cavallo-Perin P, et al. Insulin resistance and hyperinsulinemia in homozygous beta-thalassemia. Metabolism 1995;44(3):281-6.
79. De Sanctis V, et al. Insulin dependent diabetes in thalassaemia. Arch Dis Child 1988;63(1):58-62.
80. Magro S, et al. Hypothyroidism in patients with thalassemia syndromes. Acta Haematol 1990; 84(2):72-6.
81. Gabutti V, Borgna-Pignatti C. Clinical manifestations and therapy of transfusional haemosiderosis. Baillieres Clin Haematol 1994;7(4):919-40.
82. Cohen AR, Martin MB. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998;339(23):1713-4.
83. Wonke B, Wright C, Hoffbrand AV. Combined therapy with deferiprone and desferrioxamine. Br J Haematol 1998;103(2):361-4.
84. Jensen CE, et al. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103(4):911-5.
85. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann NY Acad Sci 1998;850:344-8.
86. De Sanctis V, et al. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155(5):368-72.
87. Voskaridou E, et al. Bone resorption is increased in young adults with thalassaemia major. Br J Haematol 2001;112(1):36-41.
88. Wonke B. Bone disease in beta-thalassaemia major. Br J Haematol 1998;103(4):897-901.
89. Cunningham-Rundles S, et al. Effect of transfusional iron overload on immune response. J Infect Dis 2000;182(Suppl 1):S115-21.
90. Pattanapanyasat K, et al. Lymphocyte subsets and specific T-cell immune response in thalassemia. Cytometry 2000;42(1):11-7.
91. Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood 2002;99(1):36-43.
92. Singer ST, et al. Alloimmunization and erythrocyte autoimmunization in transfusion-dependent thalassemia patients of predominantly Asian descent. Blood 2000;96(10):3369-73.
93. Kruatrachue M, et al. An association between thalassemia and autoimmune haemolytic anaemia (AHIA). Scand J Haematol 1980;25:259-63.
94. Bush S, Mandel FS, Giardina PJ. Future orientation and life expectations of adolescents and young adults with thalassemia major. Ann NY Acad Sci 1998;850:361-9.
95. Politis C. The psychosocial impact of chronic illness. Ann NY Acad Sci 1998;850:349-54.
96. Wainscoat JS, Thein SL, Weatherall DJ. Thalassaemia intermedia. Blood Rev 1987;1(4):273-9.
97. Ho PJ, et al. Beta-thalassaemia intermedia: is it possible consistently to predict phenotype from genotype? Br J Haematol 1998;100(1):70-8.
98. Styles LA. Hemoglobin H-Constant Spring Disease: an under recognized, severe form of α thalassemia. International Journal of Hematology/Oncology 1997;4(1):69-74.
99. Gratwick GM, et al. Thalassemic osteoarthropathy. Ann Intern Med 1978;88(4):494-501.
100. Olivieri NF, Weatherall DJ. The therapeutic reactivation of fetal haemoglobin. Hum Mol Genet 1998;7(10):1655-8.
101. Winichagoon P, et al. Severity differences in beta-thalassaemia/haemoglobin E syndromes: implication of genetic factors. Br J Haematol 1993;83(4):633-9.
102. Fucharoen S, Winichagoon P. Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr Opin Hematol 2000;7(2):106-12.
103. Weatherall D. Hemoglobin E β-thalassemia: an increasingly common disease with some diagnostic pitfalls. J Pediatr 1998;132(5):765-7.
104. Lucarelli G, et al. Bone marrow transplantation in thalassemia. The experience of Pesaro. Ann NY Acad Sci 1998;850:270-5.
105. Giardini C, Lucarelli G. Bone marrow transplantation for beta-thalassemia. Hematol Oncol Clin N Am 1999;13(5):1059-64 [viii].
106. Lucarelli G, et al. Bone marrow transplantation in adult thalassemic patients. Blood 1999;93(4):1164-7.
107. Storb R, et al. Current and future preparative regimens for bone marrow transplantation in thalassemia. Ann NY Acad Sci 1998;850:276-87.
108. Kelly P, et al. Umbilical cord blood stem cells: application for the treatment of patients with hemoglobinopathies. J Pediatr 1997;130(5):695-703.
109. Gaziev D, et al. Bone marrow transplantation from alternative donors for thalassemia: HLA-phenotypically identical relative and HLA-nonidentical sibling or parent transplants. Bone Marrow Transplant 2000;25(8):815-21.
110. Angelucci E, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood 1997;90(3):994-8.
111. Persons DA, Niennhuis AW. Gene therapy for the hemoglobin disorders: past, present, and future. Proc Natl Acad Sci USA 2000;97:5022-4.
112. May C, et al. Successful treatment of murine beta-thalassemia intermedia by transfer of the human beta-globin gene. Blood 2002;99(6):1902-8.
113. Cunningham JM, Jane SM. Hemoglobin switching and fetal hemoglobin reactivation. Semin Hematol 1996;33(1):9-23.
114. Pearson HA. Pharmacologic manipulation of fetal hemoglobin levels in sickle cell diseases and thalassemia: promise and reality. Adv Pediatr 1996;43:309-34.